Abstract
Introduction
Dyslipidemia usually comprises an increase in serum total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C), and a decrease in high density lipoprotein cholesterol (HDL-C), either singly or in combination.
1 Long term dyslipidemia results in vascular changes and dysfunction. 2 Therefore, dyslipidemia is recognized as a risk factor in the initiation and development of atherosclerosis and cardiovascular diseases. 3, 4 It has also been shown 
Material and Methods
The study was conducted on24 male Wistar rats (200-225 gm) after receiving approval from the institutional ethics committee of King George's Medical University, Lucknow. The rats were divided into four groups of six each. Initially, all the groups were kept on Hindustan Lever Food Pellets and water ad libitum. They were put in cages and kept in a temperature and humidity controlled room with a 12-hour light-darkcycle. After acclimatization, group I (normal diet control) continued to receive normal pellet diet. Group II was switched to fructose-rich high fat diet (F-HFD) to induce dyslipidemia. F-HFD (1 kg) was prepared by mixing 610 gm of normal pellet diet, 280 gm of ground nut oil, 5 gm of cholesterol, 5 gm of deoxycholic acid and 100 gm of fructose. Group III was given F-HFD and oral isovaleric acid (25 mg/kg of body weight/day) isolated from V. wallichi. Group IV was given F-HFD and oral atorvastatin (10 mg/kg of body weight/day). At the end of experimental period (30 days), blood samples were collected from retro-orbital plexus of each rat in EDTA tubes, and plasma was separated by centrifugation. Plasma cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C)and low density lipoprotein cholesterol (LDL-C) were measured by CHOD-PAP,GPO-POD, PEG-PAP and immunoturbidimetric methods. 8, 9, 10, 11, 12 Very low density lipoprotein cholesterol (VLDL-C) was calculated by Friedewald formula. 13 Estimation of free fatty acids (FFA) was done by the method of Monsinger et al. 14 Phospholipids in plasma were determined by Malachite green method. 15 Plasma lecithin cholesterol acyltransferase (LCAT) activity was measured by the method of Albers et al. 16 Wind and Robinson method was used to measure post heparin lipolytic activity (PHLA).
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Statistical Analysis
InStat3 package was used for statistical analysis. The mean± SD of different groups were compared by using one way analysis of variance (ANOVA), followed by Student-Newman-Keuls test. P<0.05 was considered significant. Table 1shows that plasma TC, TG, LDL-C, VLDL-C and HDL-C of group II were significantly higher as compared to group I. This shows that feeding F-HFD for 30 days induced significant dyslipidemia. Plasma TC, TG, LDL-C, VLDL-C and HDL-C of group III and IV were significantly lower as compared to group II. This shows that administration of isovaleric acid or atorvastatin together with F-HFD prevented dyslipidemia. No significant difference was seen in the plasma TC, TG, LDL-C, VLDL-C and HDL-C of group III and group IV. This means that the anti-dyslipidemic effect of isovaleric acid was comparable to that of atorvastatin. Table 2 shows the plasma free fatty acids, phospholipids, LCAT and PHLA levels in different groups. No significant difference was found in the phospholipids, LCAT and PHLA levels of group I and group II but plasma free fatty acids were higher in group II. In group III and group IV, plasma free fatty acids, phospholipids and PHLA were significantly lower and LCAT significantly higher as compared to group II. Plasma free fatty acids, phospholipids, LCAT and PHLA levels of group III and group IV were comparable. 
Results
1 Effects of feeding normal diet, fructose rich-high fat diet (F-HFD), F-HFD+isovaleric acid and F-HFD+ atorvastatin for 30 days on plasma lipids in male Wistar
Discussion
The aim of the present study was to explore the anti-dyslipidemic activity of a compound isolated from the extract of V. wallichi, namely isovaleric acid. Atorvastatin was used as a reference drug for comparison. Dyslipidemia was induced in rats by feeding them fructose rich-high fat diet (F-HFD).
Our results show that: (i) feeding F-HFD resulted in significant dyslipidemia, (ii) both isovaleric acid and atorvastatin were able to prevent dyslipidemia caused by F-HFD and (iii) the antidyslipidemic effects of atorvastatin and isovalericacid were comparable. Feeding F-FHD also increased plasma FFA but had no effect on plasma phospholipids, LCAT and PHLA. In the group given isovaleric acid together with F-HFD, plasma FFA, phospholipids and PHLA were significantly lower and LCAT significantly higher as compared to the group given F-HFD alone. Similar results were obtained in the group given atorvastatin together with F-HFD. The effects of atorvastatin and isovaleric acid were comparable. Thus, isovaleric acid emerges as a potential antidylipidemic agent having an efficacy similar to that of atorvastatin, an established antidyslipidemic drug. We have not gone into the mechanism of action of isovaleric acid but the change in plasma LCAT activity seems to provide a clue. Studies have revealed a possible association between plasma cholesterol level and LCAT activity. 18, 20 Extrahepatic cholesterol is transported to liver by HDL. 18 For this, cholesterol present in other lipoproteins has to be transferred to HDL. This transfer takes place with the help of
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LCAT. 19, 20 Thus, increased LCAT activity might be one of the reasons for the anti-dyslipidemic effect of isovaleric acid. There might be other reasons too.
One limitation of the present study was its small sample size. Secondly, it is to be seen whether the results obtained in Wistar rats can be replicated in human beings. Safety of isovaleric acid also needs to be established. Yet, the results of the present study show the need for further investigation into the anti-dyslipidemic activity of isovaleric acid in animals and humans.
Conclusion
Isovaleric acid is as effective as atorvastatin in preventing diet-induced dyslipidemia in rats.
Further research on its anti-dyslipidemic potential is warranted in animals and humans.
